Literature DB >> 2786033

Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.

L P Kahl1, C A Scott, R Lelchuk, G Gregoriadis, F Y Liew.   

Abstract

Efficacy of vaccination against cutaneous leishmaniasis in highly susceptible BALB/c mice was assessed comparatively by using radiation-attenuated promastigotes and colloidal Ag mixtures generated from a mixed Leishmania major (LV39) isolate (SLV39) and from a virulent cloned line (SVJ2) derived from the Jericho 2 L. major isolate. Dehydration-rehydration vesicle (DRV) liposomes were used as adjuvants. In optimization experiments phospholipid composition of DRV was varied, and the distearoyl derivative (DSPC) (liquid-crystalline phase transition temperature (Tc) 54 degrees C) of egg lecithin L-alpha-phosphatidylcholine was found to be superior to the dipalmitoyl derivative (DPPC, Tc 41.5 degrees C) and underivatized L-alpha-phosphatidylcholine (Tc -10 degrees C). The criteria studied were in vivo priming for a secondary in vitro proliferative response and the prepatency of lesion onset after L. major challenge of mice immunized once i.v. A single s.c. immunization with SLV39 either free or entrapped within DSPC liposomes primed spleen cells to produce significant levels of IL-3 when stimulated with SLV39 in vitro. In contrast, the i.v. route of immunization with the same Ag preparations led to little or no IL-3 production by the spleen cells. Despite development of significant T cell activation, both SLV39 and SVJ2 administered s.c., either free or entrapped within liposomes, were not protective. However, i.v. immunization four times with SVJ2 entrapped within DSPC liposomes induced a level of resistance comparable with that of 2 x 10(7) gamma-irradiated promastigotes in the stringent BALB/c L. major model. Although significant, protection conferred after i.v. immunization with SLV39/DSPC liposomes was less effective. These data therefore show that DSPC/DRV liposomes, although a good adjuvant for inducing protective immunity to cutaneous leishmaniasis, are not able to overcome the requirement for an i.v. route of immunization with the leishmanial Ag preparation. Additionally, they demonstrate a correlation between IL-3 secretion and non-protection. They also suggest that SVJ2 represents a better source of protective Ag than SLV39.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2786033

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

Review 1.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

Review 2.  Liposomal adjuvant development for leishmaniasis vaccines.

Authors:  Anis Askarizadeh; Mahmoud Reza Jaafari; Ali Khamesipour; Ali Badiee
Journal:  Ther Adv Vaccines       Date:  2017-11-15

3.  Characterization of Leishmania major antigen-liposomes that protect BALB/c mice against cutaneous leishmaniasis.

Authors:  L P Kahl; R Lelchuk; C A Scott; J Beesley
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

4.  Biochemical and biological characterization of the protective Leishmania pifanoi amastigote antigen P-8.

Authors:  M Colmenares; M Tiemeyer; P Kima; D McMahon-Pratt
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

5.  Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani.

Authors:  R Garg; S K Gupta; P Tripathi; S Naik; S Sundar; A Dube
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

6.  Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice.

Authors:  Farhat Afrin; Ravindran Rajesh; Khairul Anam; Meenakshisundram Gopinath; Swati Pal; Nahid Ali
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

7.  Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes.

Authors:  F Afrin; N Ali
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

8.  Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis.

Authors:  L Soong; S M Duboise; P Kima; D McMahon-Pratt
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection.

Authors:  D McMahon-Pratt; D Rodriguez; J R Rodriguez; Y Zhang; K Manson; C Bergman; L Rivas; J F Rodriguez; K L Lohman; N H Ruddle
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

10.  Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins.

Authors:  P Andersen
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.